Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Sarcoma 2Thoracic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 137Skin Neoplasms 21Neoplasm Metastasis 19Carcinoma, Renal Cell 16Kidney Neoplasms 15Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Sezary Syndrome 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Lymphoma 5Carcinoma, Merkel Cell 5Uveal Melanoma 4Uterine Cervical Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Neoplasms 3Urinary Bladder Neoplasms 2Testicular Neoplasms 2Testicular Germ Cell Tumor 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 2Melanoma, Experimental 2Lymphoma, Non-Hodgkin 2

Interventions

fludarabine phosphate 1fludarabine 1entinostat 1carboxyamido-triazole 1aldesleukin 1Thalidomide 1Paclitaxel 1Fentanyl 1Docetaxel 1Cyclophosphamide 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningioma × aldesleukin × Dermatologic × Clear all
NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡